Acquisition BenefitsThe acquisition of NeuroMetrix is expected to be accretive to both the top and bottom line for ECOR, increasing the company’s total addressable market and diversifying its portfolio of non-invasive wellness products.
Financial HealthECOR has no debt and has enough capital to sustain current operations, with cash and marketable securities of $12.2M.
Revenue GrowthECOR's strong performance in 4Q24 marked its ninth consecutive quarter of record revenue, reflecting deeper penetration within the VA/DoD channel and broader adoption of its Truvaga line of OTC wellness devices.